Marije B. Overdijk

2.1k citations

32 papers · 1.5k indexed · h-index 19

Hematology top 2%
Molecular Biology
Oncology top 5%
Immunology top 10%
Radiology, Nuclear Medicine and Imaging top 5%

Co-authors: Paul W.H.I. Parren Jeroen J. Lammerts van Bueren Richard W.J. Groen Sandra Verploegen Wim K. Bleeker Jeanette H.W. Leusen Esther C.W. Breij Tuna Mutis
Topics: Monoclonal and Polyclonal Antibodies Research (16 papers)Chronic Lymphocytic Leukemia Research (7 papers)Mycobacterium research and diagnosis (6 papers)
Cited by: Hematology Physiology Genetics
Journals: Journal of Clinical Oncology Blood The Journal of Immunology
Partner nations: Netherlands United States Belgium

In The Last Decade

Marije B. Overdijk

32 papers receiving 1.5k citations

Peers

Countries citing papers authored by Marije B. Overdijk

Since Specialization

Citations

This map shows the geographic impact of Marije B. Overdijk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marije B. Overdijk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marije B. Overdijk more than expected).

Fields of papers citing papers by Marije B. Overdijk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marije B. Overdijk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marije B. Overdijk. The network helps show where Marije B. Overdijk may publish in the future.

Co-authorship network of co-authors of Marije B. Overdijk

This figure shows the co-authorship network connecting the top 25 collaborators of Marije B. Overdijk. A scholar is included among the top collaborators of Marije B. Overdijk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marije B. Overdijk. Marije B. Overdijk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism 2020 ·Molecular Cancer Therapeutics ·Marije B. Overdijk,Kristin Strumane,Frank J. Beurskens,Antonio Ortiz Buijsse,Claudine Vermot‐Desroches,(unknown),Thessa Kroes,(unknown),(unknown),Richard G. Hibbert,Andreas Lingnau,Ulf Forssmann,Janine Schuurman,Paul W.H.I. Parren,Rob N. de Jong,Esther C.W. Breij	36
2	DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies 2020 ·Blood Cancer Journal ·Simone C. Oostindie,Hilma J. van der Horst,Laurens P. Kil,Kristin Strumane,Marije B. Overdijk,Edward N. van den Brink,(unknown),(unknown),Berris van Kessel,(unknown),Martine E.D. Chamuleau,Tuna Mutis,Margaret A. Lindorfer,Ronald P. Taylor,Janine Schuurman,Paul W.H.I. Parren,Frank J. Beurskens,Esther C.W. Breij	49
3	Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies 2020 ·HemaSphere ·Hilma J. van der Horst,Simone C. Oostindie,Saskia A.G.M. Cillessen,(unknown),Marije B. Overdijk,Inger S. Nijhof,Sonja Zweegman,Martine E.D. Chamuleau,Esther C.W. Breij,Tuna Mutis	5
4	Abstract 2391: DR5 agonist activity of HexaBody®-DR5/DR5 (GEN1029) is potentiated by C1q and independent of Fc-gamma receptor binding in preclinical tumor models 2019 ·Cancer Research ·Marije B. Overdijk,Kristin Strumane,Antonio Ortiz Buijsse,Claudine Vermot‐Desroches,Thessa Kroes,(unknown),(unknown),Frank J. Beurskens,Rob N. de Jong,Andreas Lingnau,Paul W.H.I. Parren,Ulf Forssmann,A. Kate Sasser,Janine Schuurman,Esther C.W. Breij	8
5	Abstract 2391: DR5 agonist activity of HexaBody^®-DR5/DR5 (GEN1029) is potentiated by C1q and independent of Fc-gamma receptor binding in preclinical tumor models 2019 ·Immunology ·Marije B. Overdijk,Kristin Strumane,Antonio Ortiz Buijsse,Claudine Vermot‐Desroches,Thessa Kroes,(unknown),(unknown),Frank J. Beurskens,Rob N. de Jong,(unknown),Paul W.H.I. Parren,Ulf Forssmann,(unknown),Janine Schuurman,Esther C.W. Breij	1
6	Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples 2018 ·Blood ·Hilma J. van der Horst,Simone C. Oostindie,Saskia A.G.M. Cillessen,(unknown),Marije B. Overdijk,Martine E.D. Chamuleau,Esther C.W. Breij,Tuna Mutis	1
7	Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding 2017 ·Blood ·Hilma J. van der Horst,Marije B. Overdijk,Esther C.W. Breij,Martine E.D. Chamuleau,Henk M. Lokhorst,Tuna Mutis	4
8	The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking 2016 ·The Journal of Immunology ·Marije B. Overdijk,J.H. Marco Jansen,Maaike Nederend,Jeroen J. Lammerts van Bueren,Richard W.J. Groen,Paul W.H.I. Parren,Jeanette H.W. Leusen,Péter Boross	196
9	Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma 2015 ·mAbs ·Marije B. Overdijk,Sandra Verploegen,Marijn Bögels,Marjolein van Egmond,Jeroen J. Lammerts van Bueren,Tuna Mutis,Richard W.J. Groen,Esther C.W. Breij,Anton C. Martens,Wim K. Bleeker,Paul W.H.I. Parren	370
10	Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression 2012 ·Neoplasia ·Stefanie Derer,Sven Berger,(unknown),Tanja Schneider‐Merck,Katja Klausz,Stefan Lohse,Marije B. Overdijk,Michael Dechant,Christian Kellner,Iris Nagelmeier,Andreas H. Scheel,Jeroen J. Lammerts van Bueren,Jan G. J. van de Winkel,Paul W.H.I. Parren,Matthias Peipp,Thomas Valerius	18
11	Crosstalk between Human IgG Isotypes and Murine Effector Cells 2012 ·The Journal of Immunology ·Marije B. Overdijk,Sandra Verploegen,Antonio Ortiz Buijsse,Tom Vink,Jeanette H.W. Leusen,Wim K. Bleeker,Paul W.H.I. Parren	157
12	Hsp70 vaccination-induced antibodies recognize B cell epitopes in the cell wall of Mycobacterium avium subspecies paratuberculosis 2011 ·Vaccine ·Wiebren Santema,Peter van Kooten,Aad Hoek,Mariska Leeflang,Marije B. Overdijk,Victor P. M. G. Rutten,Ad P. Koets	13
13	N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation 2011 ·Haematologica ·Richard W.J. Groen,Martin F. M. de Rooij,Kinga A. Kocemba‐Pilarczyk,Rogier M. Reijmers,(unknown),Marije B. Overdijk,(unknown),Henk Rozemuller,Anton C. Martens,P. Leif Bergsagel,Marie José Kersten,Steven T. Pals,Marcel Spaargaren	32
14	Susceptibility to paratuberculosis infection in cattle is associated with single nucleotide polymorphisms in Toll-like receptor 2 which modulate immune responses against Mycobacterium avium subspecies paratuberculosis 2009 ·Preventive Veterinary Medicine ·Ad P. Koets,Wiebren Santema,(unknown),(unknown),(unknown),Marije B. Overdijk,Rodrigo Labouriau,P. Franken,A. C. J. Frijters,M. Nielen,Victor P. M. G. Rutten	72
15	Searching for proteins of Mycobacterium avium subspecies paratuberculosis with diagnostic potential by comparative qualitative proteomic analysis of mycobacterial tuberculins 2009 ·Veterinary Microbiology ·Wiebren Santema,Marije B. Overdijk,(unknown),Jeroen Krijgsveld,Victor P. M. G. Rutten,Ad P. Koets	20
16	Illegitimate WNT Pathway Activation by β-Catenin Mutation or Autocrine Stimulation in T-Cell Malignancies 2008 ·Cancer Research ·Richard W.J. Groen,Monique E.C.M. Oud,Esther J.M. Schilder-Tol,Marije B. Overdijk,Derk ten Berge,Roel Nusse,Marcel Spaargaren,Steven T. Pals	38
17	Development of Conventional and Real-Time Nucleic Acid Sequence-Based Amplification Assays for Detection of Chlamydophila pneumoniae in Respiratory Specimens 2006 ·Journal of Clinical Microbiology ·Katherine Loens,Terry Beck,Herman Goossens,D. Ursi,Marije B. Overdijk,Peter Sillekens,M. Ieven	24
18	Development of conventional and real-time NASBA® for the detection of Legionella species in respiratory specimens 2006 ·Journal of Microbiological Methods ·Katherine Loens,Terry Beck,Herman Goossens,D. Ursi,Marije B. Overdijk,Peter Sillekens,Margareta Ieven	18
19	Cytokine gene expression profiles of bovine dendritic cells after interaction with Mycobacterium avium ssp. paratuberculosis (M.a.p.), Escherichia coli (E. coli) or recombinant M.a.p. heat shock protein 70 2005 ·Veterinary Immunology and Immunopathology ·Merel Langelaar,Corinna Weber,Marije B. Overdijk,Kerstin Müller,Ad P. Koets,Victor P. M. G. Rutten	16
20	Mycobacterial 70kD heat-shock protein is an effective subunit vaccine against bovine paratuberculosis 2005 ·Vaccine ·Ad P. Koets,Aad Hoek,Merel Langelaar,Marije B. Overdijk,Wiebren Santema,P. Franken,Willem van Eden,Victor P. M. G. Rutten	78

About Marije B. Overdijk

Marije B. Overdijk is a scholar working on Microbiology, Radiology, Nuclear Medicine and Imaging and Small Animals, having authored 32 papers that have together received 1.5k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (16 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Mycobacterium research and diagnosis (6 papers). The work is most often cited by research in Hematology (620 citations), Physiology (106 citations) and Genetics (223 citations). Marije B. Overdijk has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Paul W.H.I. Parren, Jeroen J. Lammerts van Bueren, Richard W.J. Groen, Sandra Verploegen, Wim K. Bleeker, Jeanette H.W. Leusen, Esther C.W. Breij, Tuna Mutis, Anton C. Martens and Marjolein van Egmond. Their work appears in journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact